We ran a 12-week clinical trial. Here's what happened.

Newsletters

Real results, not marketing.

to the archive

Sunday, July 19, 2026

I · M · 8 promotes its Daily Ultimate Essentials supplement, citing results from a 12-week clinical trial. The trial reportedly showed improvements in energy, digestion, sleep, and mental clarity among participants. I · M · 8 invites customers to ask questions about the product through a partnership with ClinicianAI.

Read this email as text

for screen readers, or when images don't load

Most supplement brands say "backed by science" and mean "we read a study once."

We ran our own study.

In a 12-week randomised, controlled clinical trial of IM8 Daily Ultimate Essentials:

95% of participants reported a noticeable boost in daily energy

85% experienced less bloating and improved digestion

80% reported better sleep

75% noticed sharper focus and mental clarity

Twelve weeks. One sachet a day. That's the entire protocol.

You've seen the claims everywhere else. This is what evidence looks like.

We've teamed up with ClinicianAI so that you can ask any question you may have about IM8.

Ask ClinicianAI about IM8 Daily Ultimate Essentials Pro here.

To your health,

Email headers

sender, ESP fingerprints, unsubscribe and auth headers

As received, minus the delivery side: the archive's own addresses appear as [recipient], relay hops and signatures are left out, and unsubscribe links are trimmed to their host.

Received-SPF: pass ([receiver]: domain of bounce-kl_26813453670-kl_101101kxxbed3pgy77ts-h-6b328f19b3=2@k3.send.im8health.com designates 170.203.16.21 as permitted sender) receiver=[receiver]; client-ip=170.203.16.21; envelope-from="bounce-kl_26813453670-kl_101101kxxbed3pgy77ts-h-6b328f19b3=2@k3.send.im8health.com"; helo=kl-203-16-21.kmta.shared.klaviyomail.com;
Authentication-Results: [receiver]; dkim=pass header.d=shared.klaviyomail.com header.s=def1 header.b=Qtjej9qO; dkim=pass header.d=send.im8health.com header.s=mtd1 header.b=exJg5ow+; dmarc=pass header.from=im8health.com policy.dmarc=quarantine; spf=none ([receiver]: no SPF records found for [email protected]) smtp.helo=kl-203-16-21.kmta.shared.klaviyomail.com; spf=pass ([receiver]: domain of bounce-kl_26813453670-kl_101101kxxbed3pgy77ts-h-6b328f19b3=2@k3.send.im8health.com designates 170.203.16.21 as permitted sender) smtp.mailfrom=bounce-kl_26813453670-kl_101101kxxbed3pgy77ts-h-6b328f19b3=2@k3.send.im8health.com; arc=none smtp.remote-ip=170.203.16.21
X-Mailer-Info-Extra2: 05f78a7043:0wc0dzN5dGczQWZihHerFDMxEDMx8FbrBwcAc mcv5SZ2lGajJXY49mYulGQ40WaAIHAxIjLx4CNuATMAA3bAEjMtYTMtMDMy0CbrBgbvBQ NxAQavBQbvNmLslWYt9WepZXYstmLkVmchh2cuEGdttmLxITL2ETLzAjMtw2aAg2bAIzX odWaoBgbtBwN3kDAp1GAt92YugGdsFWZohTbp5CZuV2cuMzaAJTPzIWOxYGOyMjY20Cat MHd3cTenB3MkVmY4h3axATMxATMfx2atAzN2MTN0MTM4YjMfx2atU2YuV3biBgZtBgMfh 2ZphGAtBAM3YzM1QzMxgjNy8FbrBAbAMFV3cTWHB1MEVkQYh1SxATMxATMAkGA91nIsFW duFWbiojI4JCLickRNljV4s0SO1ESZFDUIJ0R4MENEhFWLFDMiojItRnIsgDNwIzN0QDO 3EjOiQnIsIiURRUQLljNR1kWTR1N3k1RQNDRFJEWYtUMwIiOi0mIsATNwIzN0QDO3EjOi QHaiwSM6ISbhNmIsIyRzlWdHNlI6IyYisnOickRNljV4s0SO1ESZFDUIJ0R4MENEhFWLF DMisHIAMGA0IWZldTO2QDZ1IjY++
X-Mailer-Info: 10.sGbfJjN4EzM0UzM2cDM.sGbfFDMxEDMxsGe4JWZkNDcnl3N3Q3c.kWb4AUa uJ2b4FmcjhWa2VmLvJ3Z.gsnIwEzSYhFR0MEOHJESQFTWI1kTLtEOWlTTGdkI6snIjJiOiM1R1l2 cHJCLiMWYtJiOxwiIoRnI6EzN4QDN3IDM1ADLi0mI6ICMxsEWYJURENDUHl1N3Q1Ua1UU2kzSBRU USJCLiQnI6EzN4QDN3IDM0gDLiQXbiojIwEzSYhFR0MEOHJESQFTWI1kTLtEOWlTTGdkIsICeioj ItFmb1FGbi0Xf..EDMxEDMxsEWYJURENDUHl1N3Q1U..
X-Mailer-Info-Extra: 6b328f19b3:0wUUdzNZdEUzQURChFWLFDMxEDMxAQaA0XfiwW Y15WYtJiOignIsIyRG1UOWhzSL5UTIlVMQhkQHhzQ0QEWYtUMwIiOi0GdiwCO0AjM3QDN 4cTM6ICdiwiISFFRBtUO2EVTaNFV3cTWHB1MEVkQYh1SxAjI6ISbiwCM1AjM3QDN4cTM6 ICdoJCLxojItF2YiwiIHNXa1d0UiojIjJye6IyRG1UOWhzSL5UTIlVMQhkQHhzQ0QEWYt UMwIyegAwYAcmcv5SZ2lGajJXY49mYulGQ40Wa++
CFBL-Address: [email protected]; report=arf
Date: Sun, 19 Jul 2026 14:40:50 +0000
List-Unsubscribe: <https://manage.kmail-lists.com/…>, <mailto:…@shared.klaviyomail.com>
List-Unsubscribe-Post: List-Unsubscribe=One-Click
MIME-Version: 1.0
Message-ID: <[email protected]>
Subject: We ran a 12-week clinical trial. Here's what happened.
X-Kmail-Account: SGuisG
X-Kmail-Message: 01KXXBED3PGY77TSZMQ69KADQR
X-Kmail-Ops: 01KXF2H151SCGNKCXBVWVN9BER
X-Report-Abuse: Please report any spam or abuse to: [email protected]
From: "IM8" <[email protected]>
Content-Type: multipart/alternative; boundary=7a0e7bae525639a97575eafc45dc883a0a80467539410279ee94b33ddc15

Archived for reference and commentary. I · M · 8, its logos and content are the property of their respective owners; Inbox Archive claims no affiliation and has disabled all links. If you own this content and would like it removed, get in touch.